Nine amino acids. Discovered in the 1970s by chasing what made sleeping rabbits' blood different from waking ones. And still one of the quieter sleep compounds in the peptide space.
🔑 Key Takeaways
- DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide isolated in 1974 by the Swiss Schoenenberger-Monnier group from the cerebral venous blood of rabbits in deep sleep
- The primary documented effect is modulation of delta-wave (slow-wave) sleep architecture. Secondary effects include growth hormone release, cortisol reduction, and modulation of opioid tolerance
- Community use is almost always injectable. Typical protocols are 100 to 500 mcg subcutaneously before bed, cycled 5 to 10 days at a time
- Side effects are mild and uncommon: morning grogginess at higher doses, occasional vivid dreams, mild injection-site reactions. No serious adverse events have been reported in published research
- Not FDA approved for any indication. Sold as a lab-use compound in most markets. Classified as "emideltide" in some pharmacological contexts
- Does not cause dependence or next-day cognitive impairment the way benzodiazepines or Z-drugs do, which is one of the main reasons it attracts interest
- Research interest extends to opioid withdrawal (one historical Russian trial reported symptom relief in 97% of opiate-dependent and 87% of alcohol-dependent participants) and cancer geroprotection (animal studies)
- Not recommended for anyone on benzodiazepines, Z-drugs, MAOIs, or with unstable mood disorders without physician supervision
This page is the full reference on DSIP peptide: chemistry, discovery, mechanism, every documented benefit, community dosing protocols, side effects, contraindications, comparison to other sleep peptides, and research status in 2026.
What Is DSIP?
A nine-amino-acid neuropeptide discovered half a century ago.
Delta sleep-inducing peptide (DSIP) is a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its molecular weight is about 850 daltons, small enough to cross the blood-brain barrier, and it is amphiphilic, meaning it has both water-loving and lipid-loving regions that help it interact with neural tissue.
DSIP at a Glance
- Chemical name: Delta sleep-inducing peptide (DSIP)
- Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Alternative name: Emideltide
- Amino acids: 9 (nonapeptide)
- Molecular weight: ~850 daltons
- Discovery: 1974, Schoenenberger-Monnier group (University of Basel, Switzerland)
- Source: Isolated from cerebral venous blood of sleeping rabbits
- In vitro half-life: ~15 minutes (degraded by aminopeptidase-like enzymes)
- Classification: Naturally occurring neuropeptide
- Research status: Decades of published work, no FDA approval
DSIP is present in multiple tissues beyond the brain, including human breast milk. The name came from its original observed effect on delta (slow-wave) EEG activity in the rabbit brain assays used during its discovery. It has been studied in Russia, Europe, and the US across nearly 50 years with peaks of interest in the 1980s (sleep research), 1990s (opioid withdrawal clinical work), and from 2015 onward (community use as a sleep and recovery adjunct).
How DSIP Works
The mechanism is still imperfectly understood, and that is part of why research has not progressed to approved clinical use.
What researchers have documented across published work:
- Blood-brain barrier crossing: DSIP's small size and amphiphilic structure allow it to enter the central nervous system after subcutaneous injection, unlike most peptides that are blocked.
- NMDA receptor modulation: Some studies suggest DSIP influences NMDA glutamate receptors, which play a central role in sleep architecture regulation.
- Acetyltransferase activity: DSIP stimulates acetyltransferase enzyme activity via α1 adrenergic receptors, which affects melatonin production and circadian rhythm regulation.
- MAPK cascade interaction: DSIP homology with glucocorticoid-induced leucine zipper (GILZ) suggests interaction with stress-response signaling pathways.
- HPA axis modulation: DSIP decreases basal corticotropin levels and blocks cortisol release, functioning as a "stress-limiting" factor.
- Mitochondrial function: Enhances oxidative phosphorylation efficiency in mitochondria, which may relate to its fatigue-reduction and GH-release effects.
Unlike benzodiazepines or Z-drugs (zolpidem, eszopiclone), DSIP does not act through GABAergic pathways. This is why it does not produce dependence, morning cognitive impairment, or the rebound insomnia that characterize sedative-hypnotic medications.
DSIP Benefits
Six documented use cases, each backed by published research or consistent community reports.
Improved sleep quality and delta-wave sleep
The original and most-studied effect. In rabbit and human EEG studies, DSIP administration has been associated with increased spindle activity and delta (slow-wave) EEG amplitude. Slow-wave sleep is the physically restorative phase of sleep, and people with disrupted slow-wave sleep commonly report unrefreshing sleep despite adequate duration. Community users report deeper sleep, fewer nighttime awakenings, and waking up actually feeling rested within 3 to 5 days of consistent use.
Growth hormone release
DSIP has been documented to stimulate somatoliberin (GHRH) release and directly support somatotrophin (GH) secretion, while also inhibiting somatostatin (GH-inhibitor) release. This triple-path effect creates a small but consistent GH pulse that many users stack with other GH secretagogues. The effect is smaller than dedicated GH peptides like CJC-1295 or ipamorelin, but adds to the sleep-window GH release that normally occurs naturally.
Stress reduction and cortisol suppression
DSIP functions as a "stress-limiting factor" by reducing basal corticotropin and blocking cortisol release under stress conditions. This is relevant both for sleep (high evening cortisol disrupts sleep onset) and for general recovery. Users consistently report feeling less mentally wired and more able to wind down at night.
Opioid and alcohol withdrawal support
DSIP acts antagonistically on opiate receptors and has been studied in detoxification contexts. A historical Russian clinical trial reported symptom relief in 97% of opiate-dependent and 87% of alcohol-dependent participants. This research has not been replicated in modern Western trials, so these numbers should be interpreted cautiously, but the mechanism is plausible and addiction medicine continues to show occasional interest in DSIP.
Pain modulation
The opioid-receptor-antagonistic activity also extends to analgesic effects. Some community users report reduced chronic pain during DSIP cycles, though this is a secondary application and not a primary use case.
Potential anti-aging effects (investigational)
A Russian animal study reported DSIP reduced spontaneous tumor incidence 2.6-fold in mice over lifetime, reduced chromosome aberrations by 22.6%, and increased maximum lifespan by 24.1%. These are animal results that have not been replicated in humans, but they fit the general pattern of small peptides with broad regulatory effects producing durable health markers.
DSIP Dosage
Always subcutaneous, always cycled, always timed to evening.
Standard DSIP Protocol
- Typical dose: 100 to 500 mcg subcutaneously, once nightly
- Starting dose: 100 mcg for the first 2 to 3 nights to establish tolerance
- Working dose: 200 to 300 mcg for most users
- Upper range: 500 mcg for heavy-sleep-deprived cases (not a chronic dose)
- Timing: 30 to 60 minutes before intended sleep onset
- Cycle length: 5 to 10 consecutive nights
- Break: 5 to 14 days between cycles
- Frequency: No more than 2 to 3 cycles per month
DSIP is not meant for continuous daily use. The short in-vitro half-life (~15 minutes) does not mean the clinical effect is that brief (its effect on sleep architecture seems to persist longer), but community protocols consistently cycle rather than dosing every night indefinitely. Overuse beyond a few weeks at a time is associated with diminishing effect and occasionally with sleep-architecture rebound once stopped.
Reconstitution
DSIP is sold as a lyophilized powder in vials of 2 mg or 5 mg. A 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2,500 mcg/mL (2.5 mg/mL). A 250 mcg dose is 10 units on a standard U-100 insulin syringe. Use our reconstitution calculator for other vial sizes.
Storage
- Lyophilized vial: Refrigerate at 2 to 8°C for long-term storage
- Reconstituted: Refrigerate. Use within 4 to 6 weeks
- Protect from light. Do not freeze. Do not use if solution is cloudy or discolored
DSIP Side Effects
Generally mild and uncommon at standard doses.
| Side effect | Frequency | Notes |
|---|---|---|
| Mild sedation or drowsiness | Expected | This is the therapeutic effect, not a side effect per se |
| Morning grogginess | Occasional | Higher doses or late injection timing. Reduce dose or inject earlier |
| Vivid dreams or nightmares | Occasional | REM and delta sleep modulation effect. Usually resolves with continued use |
| Injection site reactions | Occasional | Redness, mild soreness. Rotate injection sites |
| Headache | Uncommon | First few days, typically resolves |
| Mood changes | Rare | Irritability or low mood if the stress-axis modulation is unwanted |
| Rebound sleep disruption after stopping | Rare | More common after long continuous use. Cycling prevents it |
No serious adverse events have been reported in published research across 50 years of study. Long-term safety in humans at daily continuous use is not well characterized, which is the main reason most protocols cycle rather than continuous-dose. Overdose is theoretically possible but has not been reported in published cases.
Who Should Not Use DSIP
Do NOT Use DSIP If You:
- Are taking benzodiazepines or Z-drugs (zolpidem, eszopiclone, zaleplon), potential additive sedation
- Are taking MAOIs or other serotonergic medications without physician supervision
- Have an unstable mood disorder (bipolar spectrum, severe depression) due to potential sleep-architecture effects
- Have a history of opioid dependence in active recovery without addiction-specialist supervision
- Are pregnant or active breastfeeding, no safety data
- Are under 18, no pediatric safety data
- Have known hypersensitivity to DSIP or any component of the formulation
- Are scheduled for surgery or general anesthesia in the next 48 hours (discuss with anesthesiologist)
DSIP vs Other Sleep Peptides and Compounds
| Compound | Mechanism | Best for | Key tradeoffs |
|---|---|---|---|
| DSIP | Delta-wave sleep modulation, HPA axis, NMDA | Deep restorative sleep, GH pulse, stress reduction | Must inject, cycling required |
| Melatonin | Circadian rhythm via MT1/MT2 receptors | Sleep onset, jet lag | Oral, no dependence, but minimal effect on sleep architecture |
| Epitalon | Pineal gland / circadian regulation | Circadian reset, anti-aging | Not a direct sleep compound, cycled use |
| Sermorelin / Ipamorelin | GH secretagogue | GH pulse at sleep onset, indirect sleep benefit | Not a primary sleep compound |
| GABA-class sedatives (benzodiazepines, Z-drugs) | GABA-A receptor modulation | Acute insomnia, short-term use | Dependence, morning cognitive impairment, rebound insomnia |
| Trazodone | Serotonin modulation, antihistamine effect | Chronic insomnia, depression-related sleep | Prescription only, next-day grogginess |
The specific case for DSIP is deep-sleep architecture restoration without dependence or morning impairment. It is not the right pick for acute single-night insomnia (where a short-acting GABA agent works faster) and it is not a circadian reset tool (melatonin is better for that). It is the right pick for people who want deeper, more restorative sleep over a 1 to 2 week cycle, particularly those whose sleep feels non-restorative despite adequate duration.
DSIP Stacks
- DSIP + sermorelin or ipamorelin: Stacks the small DSIP GH pulse with a dedicated GH secretagogue at bedtime. Common recovery-focused combination.
- DSIP + magnesium glycinate (200 to 400 mg): Non-peptide pairing that reinforces the calming effect.
- DSIP + L-theanine (200 mg) and/or glycine (3 g): Natural additions that support sleep onset.
- DSIP + Selank: For users dealing with both sleep and daytime anxiety. Selank in the morning, DSIP at night.
- DSIP + Epitalon: Cycled in tandem for combined circadian and sleep-architecture support.
Avoid stacking DSIP with benzodiazepines, Z-drugs, trazodone, or prescription sedatives without explicit physician guidance. The additive sedation can push you beyond therapeutic into risky territory.
Research Status in 2026
DSIP sits in a specific research category: decades of small studies, established pharmacology, no Phase 3 trials, no FDA approval. The historical research base is largely Russian and European from the 1980s and 1990s with a smaller Western academic trail. Modern interest is primarily from the peptide biohacking community rather than pharmaceutical development.
Why has it not progressed to approval? The dominant hypothesis among researchers is that the effect size for any single indication is modest, the mechanism is multi-pathway rather than single-target (harder to develop as a drug), and generic peptide patents limited commercial motivation for expensive Phase 3 trials. Compare this to newer peptides like GLP-1 agonists (Wegovy, Zepbound) where a single-pathway mechanism and patentable analogs made development economically viable.
Where to Buy DSIP
Quality markers matter more than price.
- ≥98% purity verified by independent HPLC and mass spectrometry
- Third-party Certificate of Analysis (COA) available per batch
- Lyophilized vials of 2 or 5 mg, sealed with butyl rubber stopper
- US-based manufacturing with cold-chain handling
- Clear batch numbers and lot documentation
Avoid any source that sells loose powder, has no independent lab verification, or ships from unknown manufacturing locations. For a broader vendor vetting walkthrough, see our best legit peptide vendors guide.